The origin of the PTE system flows from a desire to compensate those who have invested time and resources in making or finding new medical products for the additional burden of gaining regulatory approval for that product. Thus, originally, the PTE provisions were...
Warner-Lambert is proprietor of a European patent (EP 0641330) which claims the compound pregabalin (via compound per se claims). The Supplementary Protection Certificate (SPC) was (surprisingly) allowed to lapse in October 2013 for non-payment of fees resulting in...
Warner-Lambert is the proprietor of European Patent 0934061 which claims “Use of Pregablin for the preparation of a pharmaceutical composition for treating pain”. Pregablin is also used for the treatment of generalised anxiety disorder and epilepsy, although treatment...
Until now, exceptions to patent infringement in the UK were limited, so manufacturers preparing for regulatory approval risked an infringement action. Legislation will come into force in the UK on 1 October 2014 that finally provides broad exemption from patent...
Finasteride was a known treatment for benign prostatic hyperplasia and Merck were granted a patent for this therapeutic application in 1978. Subsequently, Merck filed an application for the treatment of androgenic alopecia with a family of compounds including...
Recent Comments